XML 22 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Revenues [Abstract]    
Revenue from collaborative arrangements and other contracts, including affiliated entity $ 217,756 $ 832,010
Operating expenses:    
Research and development 75,620,340 86,676,563
General and administrative 36,996,338 47,582,104
Impairment of goodwill 0 10,513,371
Total operating expenses 112,616,678 144,772,038
Loss from operations (112,398,922) (143,940,028)
Other income (expense):    
Interest income 4,766,993 8,133,290
Interest expense (177,833) (1,222,789)
Change in fair value of common stock warrant liability 2,808,608 0
(Loss) gain on investment in affiliated entity (1,166,443) 773,145
Net unrealized gain on available-for-sale equity securities 2,077,182 5,850,626
Other expense, net (3,163,711) (4,711,596)
Net loss $ (107,254,126) $ (135,117,352)
Net loss per share    
Basic (in dollars per share) $ (3.95) $ (6.09)
Diluted (in dollars per share) $ (3.95) $ (6.09)
Weighted average number of common shares outstanding    
Basic (in shares) 27,160,863 22,173,662
Diluted (in shares) 27,160,863 22,173,662